Effects of <i>Spirulina platensis</i> Supplementation on COVID-19 Severity in Critically Ill Patients: A Randomized Clinical Trial

AuthorMahdi Shadnoushen
AuthorHeitor O. Santosen
AuthorMonireh Hatamien
AuthorMehdi Norouzien
AuthorMohsen Taghavien
AuthorHenrique Santa Capita Cerqueiraen
AuthorMansoore Sadat Mojani- Qomien
AuthorHooman Bakhshandehen
AuthorJamal Rahmanien
AuthorZainab Javiden
AuthorDavood Sanaei Delir Zavaraghen
AuthorFatemeh Mikanikien
AuthorArezoo Chaharmahalien
AuthorMatin Ghanavatien
AuthorMojgan Nazarien
OrcidMahdi Shadnoush [0000-0002-3716-0994]en
OrcidHooman Bakhshandeh [0000-0002-5102-1501]en
Issued Date2024-12-31en
AbstractBackground: Spirulina is a functional food with antioxidant and anti-inflammatory properties. Its anti-inflammatory, antioxidant, antiviral, and immunomodulatory potential may improve certain clinical conditions in patients with coronavirus disease 2019 (COVID-19) in the intensive care unit (ICU). Objectives: This study aimed to investigate the effects of Spirulina supplementation on clinical conditions in critically ill patients with COVID-19. Methods: A double-blind clinical trial randomized patients admitted to an ICU to receive either Spirulina platensis supplementation (5g/day, n = 97) or to a control group (n = 95). The severity of COVID-19 was assessed using the Acute Physiology and Chronic Health Evaluation (APACHE), National Early Warning Score (NEWS) 2, and Sequential Organ Failure Assessment Score (SOFA). The study also evaluated the length of stay in the hospital and ICU, respiratory support at discharge, and 28-day mortality. In the survival analysis, 126 participants were evaluated (58 in the control group and 68 in the Spirulina group). Results: There was no significant difference between the groups in 28-day mortality (HR = 1.07, 95% CI 0.57 - 1.97) or NEWS2 (P = 0.76). However, the SOFA score significantly decreased in the Spirulina group compared to the control group (P = 0.03). The Spirulina group had a shorter ICU length of stay (7.43 ± 3.98 days) compared to the control group (10.00 ± 4.69 days, P = 0.007). The hospital length of stay was also shorter in the Spirulina group compared to the control group (P = 0.001). Conclusions: Spirulina supplementation reduced disease severity (as measured by the SOFA score) and shortened hospital and ICU length of stay in critically ill COVID-19 patients, but it did not reduce mortality.en
DOIhttps://doi.org/10.5812/jcma-149015en
Keyword<i>Spirulina platensis</i>en
KeywordCOVID-19en
KeywordMortalityen
KeywordIntensive Care Uniten
KeywordICU Length of Stayen
KeywordAdjunctive Therapyen
PublisherBrieflandsen
TitleEffects of <i>Spirulina platensis</i> Supplementation on COVID-19 Severity in Critically Ill Patients: A Randomized Clinical Trialen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
jcma-In_Press-In_Press-149015-publish-pdf.pdf
Size:
407.33 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF